Aktie 853849 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Takeda Pharmaceutical Company Limited OTC Markets

Aktien

853849

JP3463000004

TKPH.F

Markt geschlossen - OTC Markets
Andere Börsenplätze
 15:55:15 24.06.2024 		% 5 Tage % 1. Jan.
25,91 USD +3,64 % Intraday Chart für Takeda Pharmaceutical Company Limited +1,61 % -9,82 %
25.06. US CDC warnt Gesundheitsdienstleister vor Anstieg der Dengue-Fälle RE
25.06. Krebsmedikament von Takeda erhält Zulassung der Europäischen Kommission MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
US CDC alerts healthcare providers of increase in dengue cases
Takeda's Cancer Drug Gets European Commission Approval
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
Les sorcières épouvantent l'IA
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 853849 Aktie
  4. 853849 Aktie
  5. Nachrichten Takeda Pharmaceutical Company Limited
  6. Andere Sprachen